Short Interest in Mesoblast Limited (OTCMKTS:MEOBF) Increases By 25.2%

Mesoblast Limited (OTCMKTS:MEOBF) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 19,793,500 shares, a growth of 25.2% from the January 15th total of 15,809,700 shares. Based on an average daily volume of 547,700 shares, the short-interest ratio is currently 36.1 days.

Mesoblast Stock Performance

Shares of MEOBF remained flat at $1.62 during midday trading on Friday. The company has a fifty day moving average of $1.86 and a 200 day moving average of $1.21. Mesoblast has a 12-month low of $0.19 and a 12-month high of $5.34.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.